NO20092965L - Sammensetninger og fremgangsmater for a forhindre kreft med cupredoksiner - Google Patents
Sammensetninger og fremgangsmater for a forhindre kreft med cupredoksinerInfo
- Publication number
- NO20092965L NO20092965L NO20092965A NO20092965A NO20092965L NO 20092965 L NO20092965 L NO 20092965L NO 20092965 A NO20092965 A NO 20092965A NO 20092965 A NO20092965 A NO 20092965A NO 20092965 L NO20092965 L NO 20092965L
- Authority
- NO
- Norway
- Prior art keywords
- methods
- cupredoxins
- compositions
- prevent cancer
- cancer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/14—Peptides, e.g. proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/225—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Alcaligenes (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/235—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bordetella (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/28—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Vibrionaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/32—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bacillus (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/025—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Radiology & Medical Imaging (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Analytical Chemistry (AREA)
- Toxicology (AREA)
- Botany (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Vascular Medicine (AREA)
- Anesthesiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Plant Pathology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Det beskrives metoder og materialer for avlevering av en lastforbindelse til en kreftcelle. Avlevering av lastforbindelsen gjennomføres ved bruk av et protein transduksjonsdomene avledet fra cupredoxiner. Lastforbindelsen kan være en nukleinsyre og spesifikt en DNA, en RNA eller antisens. Det beskrives videre metoder for behandling av kreft og diagnostisering av kreft.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US90009807P | 2007-02-08 | 2007-02-08 | |
PCT/US2008/053493 WO2008098216A2 (en) | 2007-02-08 | 2008-02-08 | Compositions and methods to prevent cancer with cupredoxins |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20092965L true NO20092965L (no) | 2009-10-08 |
Family
ID=39682451
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20092965A NO20092965L (no) | 2007-02-08 | 2009-09-04 | Sammensetninger og fremgangsmater for a forhindre kreft med cupredoksiner |
Country Status (14)
Country | Link |
---|---|
US (2) | US8232244B2 (no) |
EP (1) | EP2114429A4 (no) |
JP (2) | JP2010518123A (no) |
KR (1) | KR20090114414A (no) |
CN (1) | CN101668536A (no) |
AU (1) | AU2008212788A1 (no) |
BR (1) | BRPI0806451A2 (no) |
CA (1) | CA2677803A1 (no) |
IL (1) | IL200251A0 (no) |
MX (1) | MX2009008508A (no) |
NO (1) | NO20092965L (no) |
RU (1) | RU2009133473A (no) |
WO (1) | WO2008098216A2 (no) |
ZA (1) | ZA200905508B (no) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7381701B2 (en) * | 2001-02-15 | 2008-06-03 | The Borad Of Trustees Of The University Of Illinois | Compositions and methods for treating conditions related to ephrin signaling with cupredoxins |
US7556810B2 (en) | 2005-07-19 | 2009-07-07 | The Board Of Trustees Of The University Of Ilinois | Compositions and methods to control angiogenesis with cupredoxins |
US9096663B2 (en) * | 2001-02-15 | 2015-08-04 | The Board Of Trustees Of The University Of Illinois | Compositions and methods for treating conditions related to ephrin signaling with cupredoxins and mutants thereof |
US10675326B2 (en) | 2004-10-07 | 2020-06-09 | The Board Of Trustees Of The University Of Illinois | Compositions comprising cupredoxins for treating cancer |
US9968685B2 (en) * | 2004-10-07 | 2018-05-15 | Brad N. Taylor | Methods to treat cancer with cupredoxins |
US9434770B2 (en) * | 2004-10-07 | 2016-09-06 | Tapas K Das Gupta | Modified cupredoxin derived peptides |
US20090208476A1 (en) * | 2006-05-19 | 2009-08-20 | Tapas Das Gupta | Compositions and methods to concurrently treat or prevent multiple diseases with cupredoxins |
US8158574B2 (en) * | 2004-10-07 | 2012-04-17 | Cdg Therapeutics, Inc. | Compositions and methods to prevent cancer with cupredoxins |
US9598470B2 (en) * | 2004-10-07 | 2017-03-21 | Craig W. Beattie | Compositions and methods to prevent cancer by stabilizing P53 through non MDM2-mediated pathways |
EA200700813A1 (ru) | 2004-10-07 | 2008-10-30 | Ананда Чакрабарти | Транспортирующие вещества, производные купредоксина и способы их применения |
WO2007012004A2 (en) | 2005-07-19 | 2007-01-25 | The Board Of Trustees Of The University Of Illinois | Transport agents for crossing the blood-brain barrier and into brain cancer cells, and methods of use thereof |
US8017749B2 (en) * | 2006-12-04 | 2011-09-13 | The Board Of Trustees Of The University Of Illinois | Compositions and methods to treat cancer with cupredoxins and CpG rich DNA |
CA2677803A1 (en) | 2007-02-08 | 2008-08-14 | The Board Of Trustees Of The University Of Illinois | Compositions and methods to prevent cancer with cupredoxins |
WO2011123795A1 (en) | 2010-04-02 | 2011-10-06 | Battelle Memorial Institute | Methods for associating or dissociating guest materials with a metal organic framework, systems for associating or dissociating guest materials within a series of metal organic frameworks, and gas separation assemblies |
WO2022018711A1 (en) * | 2020-07-22 | 2022-01-27 | Aboeimehrizi Haniyeh | P28-vpr chimeric protein with anticancer properties |
RU204475U1 (ru) * | 2020-09-24 | 2021-05-26 | Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт медицины труда имени академика Н.Ф. Измерова" (ФГБНУ "НИИ МТ") | Медицинский аппликатор для местного лечения кожных заболеваний |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5811128A (en) | 1986-10-24 | 1998-09-22 | Southern Research Institute | Method for oral or rectal delivery of microencapsulated vaccines and compositions therefor |
US5567411A (en) | 1986-11-10 | 1996-10-22 | State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of The University Of Oregon | Dendritic amplifier molecules having multiple terminal active groups stemming from a benzyl core group |
US5252317A (en) | 1986-11-10 | 1993-10-12 | The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of The University Of Oregon | Amplifier molecules for diagnosis and therapy derived from 3,5-bis[1-(3-amino-2,2-bis (aminomethyl)-propyl) oxymethyl] benzoic acid |
GB8923843D0 (en) | 1989-10-23 | 1989-12-13 | Salutar Inc | Compounds |
US5679810A (en) | 1990-01-19 | 1997-10-21 | Salutar, Inc. | Linear oligomeric polychelant compounds |
US5760191A (en) | 1993-02-05 | 1998-06-02 | Nycomed Imaging As | Macrocyclic complexing agents and targeting immunoreagents useful in therapeutic and diagnostic compositions and methods |
US5417959A (en) | 1993-10-04 | 1995-05-23 | Mallinckrodt Medical, Inc. | Functionalized aza-crytand ligands for diagnostic imaging applications |
US5801228A (en) | 1995-06-07 | 1998-09-01 | Nycomed Imaging As | Polymeric contrast agents for medical imaging |
ATE261961T1 (de) | 1995-11-17 | 2004-04-15 | Biotechnolog Forschung Gmbh | Epothilon-derivate, ihre herstellung und verwendung |
US6011029A (en) | 1996-02-26 | 2000-01-04 | Bristol-Myers Squibb Company | Inhibitors of farnesyl protein transferase |
US5804161A (en) | 1996-05-14 | 1998-09-08 | Nycomed Salutar Inc. | Contrast agents |
US6491903B1 (en) | 1996-06-27 | 2002-12-10 | Washington University | Particles comprising amphiphilic copolymers |
DE59712968D1 (de) | 1996-11-18 | 2008-10-30 | Biotechnolog Forschung Gmbh | Epothilone E und F |
US6242469B1 (en) | 1996-12-03 | 2001-06-05 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
US6441186B1 (en) | 1996-12-13 | 2002-08-27 | The Scripps Research Institute | Epothilone analogs |
US6380394B1 (en) | 1996-12-13 | 2002-04-30 | The Scripps Research Institute | Epothilone analogs |
GB9801231D0 (en) | 1997-06-05 | 1998-03-18 | Merck & Co Inc | A method of treating cancer |
WO1999002224A1 (en) | 1997-07-07 | 1999-01-21 | Lewis Robert D | Statistical analysis and feedback system for sports employing a projectile |
US6605599B1 (en) | 1997-07-08 | 2003-08-12 | Bristol-Myers Squibb Company | Epothilone derivatives |
AU9340998A (en) | 1997-08-09 | 1999-03-01 | Schering Aktiengesellschaft | New epothilone derivatives, method for producing same and their pharmaceutical use |
IT1297288B1 (it) | 1997-10-31 | 1999-09-01 | Denis Robert Gemmani | Struttura di grigliato metallico dentellato particolarmente per il completamento di manufatti ed opere edili ad uso civile od industriale |
US6365749B1 (en) | 1997-12-04 | 2002-04-02 | Bristol-Myers Squibb Company | Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs |
AU3818799A (en) | 1998-04-20 | 1999-11-08 | Basf Aktiengesellschaft | Novel heterocyclically substituted amides with cysteine protease-inhibiting effect |
US6380395B1 (en) | 1998-04-21 | 2002-04-30 | Bristol-Myers Squibb Company | 12, 13-cyclopropane epothilone derivatives |
US6498257B1 (en) | 1998-04-21 | 2002-12-24 | Bristol-Myers Squibb Company | 2,3-olefinic epothilone derivatives |
WO1999067253A2 (en) | 1998-06-22 | 1999-12-29 | Novartis Ag | Desmethyl epothilones |
AU5036999A (en) | 1998-06-30 | 2000-01-17 | Schering Aktiengesellschaft | Epothilon derivatives, their preparation process, intermediate products and their pharmaceutical use |
EP1144605B1 (en) | 1999-01-26 | 2009-12-16 | University College London | Dimethylarginine dimethylaminohydrolases |
US20020164703A1 (en) | 2000-12-21 | 2002-11-07 | Krzysztof Pawlowski | Card-domain containing polypeptides, encoding nucleic acids, and methods of use |
US7301010B2 (en) * | 2001-02-15 | 2007-11-27 | The Board Of Trustees Of The University Of Illinois | Compositions and methods for treating HIV infection with cupredoxin and cytochrome c |
US7618939B2 (en) * | 2001-02-15 | 2009-11-17 | The Board Of Trustees Of The University Of Illinois | Compositions and methods to prevent cancer with cupredoxins |
US7556810B2 (en) * | 2005-07-19 | 2009-07-07 | The Board Of Trustees Of The University Of Ilinois | Compositions and methods to control angiogenesis with cupredoxins |
US7338766B2 (en) * | 2001-02-15 | 2008-03-04 | The Board Of Trustees Of The University Of Illinois | Compositions and methods for treating malaria with cupredoxin and cytochrome |
US7491394B2 (en) * | 2001-02-15 | 2009-02-17 | The Board Of Trustees Of The University Of Illinois | Cytotoxic factors for modulating cell death |
GB0211295D0 (en) | 2002-05-16 | 2002-06-26 | Univ London | Treatment of pain |
US9434770B2 (en) * | 2004-10-07 | 2016-09-06 | Tapas K Das Gupta | Modified cupredoxin derived peptides |
US20090208476A1 (en) * | 2006-05-19 | 2009-08-20 | Tapas Das Gupta | Compositions and methods to concurrently treat or prevent multiple diseases with cupredoxins |
EA200700813A1 (ru) * | 2004-10-07 | 2008-10-30 | Ананда Чакрабарти | Транспортирующие вещества, производные купредоксина и способы их применения |
US9968685B2 (en) * | 2004-10-07 | 2018-05-15 | Brad N. Taylor | Methods to treat cancer with cupredoxins |
WO2007012004A2 (en) * | 2005-07-19 | 2007-01-25 | The Board Of Trustees Of The University Of Illinois | Transport agents for crossing the blood-brain barrier and into brain cancer cells, and methods of use thereof |
DE102006030674A1 (de) | 2006-07-04 | 2008-01-10 | Deon Ag | Verstellbare Stützeinrichtung zur flächigen Abstützung einer Polsterung eines Sitz- und/oder Liegemöbels, insbesondere einer Matratze eines Bettes |
AU2007272452A1 (en) | 2006-07-12 | 2008-01-17 | Oncotx, Inc. | Compositions and methods for targeting cancer-specific transcription complexes |
CN101600447A (zh) * | 2006-09-11 | 2009-12-09 | 伊利诺斯大学理事会 | 铜氧还蛋白衍生肽类的修饰物及其使用方法 |
WO2008033987A2 (en) * | 2006-09-14 | 2008-03-20 | The Board Of Trustees Of The University Of Illinois | Compositions and methods to prevent cancer with cupredoxins |
US8017749B2 (en) * | 2006-12-04 | 2011-09-13 | The Board Of Trustees Of The University Of Illinois | Compositions and methods to treat cancer with cupredoxins and CpG rich DNA |
CA2677803A1 (en) | 2007-02-08 | 2008-08-14 | The Board Of Trustees Of The University Of Illinois | Compositions and methods to prevent cancer with cupredoxins |
-
2008
- 2008-02-08 CA CA002677803A patent/CA2677803A1/en not_active Abandoned
- 2008-02-08 EP EP08743447A patent/EP2114429A4/en not_active Withdrawn
- 2008-02-08 BR BRPI0806451-2A2A patent/BRPI0806451A2/pt not_active IP Right Cessation
- 2008-02-08 US US12/028,683 patent/US8232244B2/en active Active
- 2008-02-08 KR KR1020097017744A patent/KR20090114414A/ko not_active Application Discontinuation
- 2008-02-08 RU RU2009133473/10A patent/RU2009133473A/ru unknown
- 2008-02-08 AU AU2008212788A patent/AU2008212788A1/en not_active Abandoned
- 2008-02-08 WO PCT/US2008/053493 patent/WO2008098216A2/en active Search and Examination
- 2008-02-08 CN CN200880009621A patent/CN101668536A/zh active Pending
- 2008-02-08 JP JP2009549275A patent/JP2010518123A/ja not_active Withdrawn
- 2008-02-08 MX MX2009008508A patent/MX2009008508A/es not_active Application Discontinuation
-
2009
- 2009-08-05 IL IL200251A patent/IL200251A0/en unknown
- 2009-08-06 ZA ZA200905508A patent/ZA200905508B/xx unknown
- 2009-09-04 NO NO20092965A patent/NO20092965L/no not_active Application Discontinuation
-
2012
- 2012-07-30 US US13/561,225 patent/US10086037B2/en active Active
-
2014
- 2014-05-28 JP JP2014110591A patent/JP2014237640A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CA2677803A1 (en) | 2008-08-14 |
WO2008098216A2 (en) | 2008-08-14 |
US20080226560A1 (en) | 2008-09-18 |
MX2009008508A (es) | 2010-04-21 |
US10086037B2 (en) | 2018-10-02 |
EP2114429A4 (en) | 2010-05-19 |
EP2114429A2 (en) | 2009-11-11 |
US8232244B2 (en) | 2012-07-31 |
JP2010518123A (ja) | 2010-05-27 |
AU2008212788A1 (en) | 2008-08-14 |
CN101668536A (zh) | 2010-03-10 |
JP2014237640A (ja) | 2014-12-18 |
US20130084247A1 (en) | 2013-04-04 |
ZA200905508B (en) | 2010-07-28 |
RU2009133473A (ru) | 2011-03-20 |
KR20090114414A (ko) | 2009-11-03 |
WO2008098216A3 (en) | 2008-12-18 |
IL200251A0 (en) | 2010-04-29 |
BRPI0806451A2 (pt) | 2014-07-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20092965L (no) | Sammensetninger og fremgangsmater for a forhindre kreft med cupredoksiner | |
Feretzaki et al. | Expression and differential regulation of human TERRA at several chromosome ends | |
Lin et al. | Luminescence switch-on detection of protein tyrosine kinase-7 using a G-quadruplex-selective probe | |
Jamonnak et al. | Yeast Nrd1, Nab3, and Sen1 transcriptome-wide binding maps suggest multiple roles in post-transcriptional RNA processing | |
WO2010018563A3 (en) | Compositions and methods for the prognosis of lymphoma | |
WO2007130604A3 (en) | Anti-tumor activity of an oncolytic adenovirus-delivered oncogene sirna | |
WO2009058913A3 (en) | Yeast cell wall protein (ycwp) encapsulated multilyered nanoparticles for nucleic acid delivery (sirna) | |
EP2274442A4 (en) | CONSENSUS SEQUENCES OF CHIKUNGUNYA VIRUS PROTEINS, NUCLEIC ACID MOLECULES ENCODING SAME, AND COMPOSITIONS AND METHODS OF USE THEREOF | |
ATE502122T1 (de) | Chemisch modifizierte oligonukleotidprimer zur nukleinsäureamplifikation | |
WO2006031901A3 (en) | SMALL INTERFERING RNAs THAT EFFICIENTLY INHIBIT VIRAL GENE EXPRESSION AND METHODS OF USE THEREOF | |
WO2008145400A3 (en) | Mutated structural protein of a parvovirus | |
WO2009012263A3 (en) | Tissue-specific micrornas and compositions and uses thereof | |
WO2006135886A3 (en) | Compositions and methods for treating and diagnosing cancer | |
WO2009039189A3 (en) | Compositions comprising stat3 sirna and methods of use thereof | |
Borrás et al. | Centenarians maintain miRNA biogenesis pathway while it is impaired in octogenarians | |
WO2008131191A3 (en) | Nucleic acids hybridizable to micro rna and precursors thereof | |
WO2010039802A3 (en) | Methods and compositions for isolating nucleic acid | |
WO2010045384A3 (en) | Short hairpin rnas for inhibition of gene expression | |
Meier et al. | Genome-wide identification of translationally inhibited and degraded miR-155 targets using RNA-interacting protein-IP | |
WO2007032794A3 (en) | Inhibition of viral gene expression using small interfering rna | |
WO2008146251A3 (en) | A primary micro rna expression cassette | |
ATE414277T1 (de) | Verfahren zur verhinderung der zeitabhängigen rna-expression in biologischen zellen | |
WO2008101216A3 (en) | Gamma satellite insulator sequences and their use in preventing gene silencing | |
Hassan et al. | Ribonucleoprotein immunoprecipitation (RNP‐IP): a direct in vivo analysis of microRNA‐targets | |
WO2009006446A3 (en) | Methods for cloning small rna species |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |